RxDoctor Payments Data

Jon Uyesaka, MD

Internal Medicine · Santa Barbara, CANPI 1801958525

Payments from drug & device makers

$8,822in general payments, 2019–2025

Across 460 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Pfizer$924
  • Novo Nordisk$914
  • Johnson & Johnson$574
  • Boehringer Ingelheim$543
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$8,822100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,822 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$303,484
Medicare patients
625
Services billed
3,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin91$94,125
EliquisApixaban97$78,236
XareltoRivaroxaban54$66,542
OzempicSemaglutide55$52,933
TrulicityDulaglutide23$28,401
ProliaDenosumab15$26,316
WegovySemaglutide19$26,233
MyrbetriqMirabegron28$23,224
MounjaroTirzepatide18$20,237
KerendiaFinerenone15$15,261
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$11,478
Praluent PenAlirocumab14$7,375
PremarinEstrogens, Conjugated18$5,772
Breo ElliptaFluticasone/Vilanterol15$5,547
SynthroidLevothyroxine Sodium65$5,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$543$94,12591 claims
PfizerEliquis, Premarin, Paxlovid$924$85,437174 claims
Novo NordiskOzempic, Wegovy$914$79,16574 claims
Johnson & JohnsonXarelto$574$66,54254 claims
Lilly USA, LLCTrulicity, Mounjaro$313$48,63941 claims
AmgenProlia$270$26,31615 claims
Astellas Pharma US IncMyrbetriq$188$23,22428 claims
GSKTrelegy Ellipta, Breo Ellipta$271$17,02527 claims
BayerKerendia$269$15,26115 claims
AbbVieSynthroid$1,263$5,52765 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →